Combination vaccine development by Pfizer and BioNTech has made significant strides, with the companies announcing key results from their Phase 3 clinical trial. The trial focused on a combined mRNA vaccine aimed at protecting against both influenza and COVID-19 in individuals aged 18 to 64. This vaccine includes Pfizer’s mRNA-based influenza candidate along with their COVID-19 vaccine. While one of the two primary immunogenicity objectives was met—showing strong responses to influenza A and SARS-CoV-2—the candidate did not achieve the desired immunogenicity for influenza B. Despite this, the companies remain optimistic about improving the vaccine’s efficacy and continuing their efforts to enhance protection against respiratory diseases.
The Phase 3 trial enrolled over 8,000 participants and was conducted in a randomized, observer-blinded format. The objective was to compare the combination vaccine with a licensed influenza vaccine and Pfizer’s existing COVID-19 vaccine administered at the same time. Encouraging results were observed with higher antibody responses to influenza A compared to the licensed flu vaccine, and comparable responses to SARS-CoV-2. However, responses to influenza B were weaker than anticipated. Pfizer and BioNTech are now focusing on adjusting the formulation to improve these results. The companies have stated that no safety concerns have emerged thus far in their ongoing review of the data, signaling strong confidence in the potential of the combination vaccine.
Next Steps for Combination Vaccine Development
Pfizer and BioNTech are evaluating potential adjustments to their combination vaccine to strengthen immune responses to influenza B. The companies are in discussions with health authorities to determine the best path forward. Meanwhile, Pfizer has also provided an update on its second-generation standalone mRNA influenza vaccine, which is currently in Phase 2 trials. The preliminary data from this trial show robust immune responses to all strains of the influenza virus, suggesting that future improvements could translate into more effective combination vaccines. The next steps for both the combination and standalone vaccines will likely focus on optimizing immunogenicity and ensuring broad protection against multiple strains of the flu and COVID-19.
Pfizer’s second-generation mRNA influenza vaccine, known as the trivalent influenza RNA vaccine (tIRV), has already shown promise in generating strong immune responses against influenza A in Phase 2 trials. This vaccine was developed as an improvement on the company’s first-generation quadrivalent RNA vaccine, which had demonstrated strong efficacy in individuals aged 18 to 64 but less effectiveness in older adults. The tIRV formulation aligns with updated recommendations from global health authorities, including the World Health Organization (WHO). With no significant safety concerns reported, Pfizer continues to work toward refining its approach to provide broader protection through next-generation mRNA technologies.
Addressing Influenza and COVID-19 with One Vaccine
The development of a combination vaccine against influenza and COVID-19 is seen as a significant innovation in the field of respiratory disease prevention. Combining these vaccines into one shot could simplify the vaccination process, reduce the burden on healthcare systems, and provide comprehensive protection against two of the most prevalent and dangerous respiratory viruses. Pfizer and BioNTech are confident that they can build on their mRNA technology to provide broader and longer-lasting protection through combination vaccines. The ongoing trials are critical in demonstrating the feasibility and effectiveness of this approach, and the companies remain committed to bringing this solution to market as soon as possible.
Despite some challenges in achieving optimal responses for influenza B, Pfizer and BioNTech’s combination vaccinecontinues to offer strong potential for addressing respiratory health on a larger scale. With further adjustments and continued research, this vaccine could revolutionize the way seasonal vaccines are administered, ensuring that people are protected against both the flu and COVID-19 with a single shot. The companies are optimistic about the future of mRNA technology and its role in shaping the next generation of vaccines, and they are dedicated to overcoming the hurdles faced in their current trials to ensure that patients receive the best possible protection.
Resource: Pfizer, August 16, 2024

This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.